Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.

Rafal Dziadziuszko Solange PetersTony MokD Ross CamidgeShirish M GadgeelSai-Hong Ignatius OuKrzysztof KonopaJohannes Noé Malgorzata NowickaWalter BordognaPeter N MorcosVlatka SmoljanovicAlice T Shaw

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

These data suggest that plasma cfDNA concentration may have prognostic value in advanced ALK+ NSCLC. Prospectively designed studies are warranted to investigate this finding.

Keyphrases

phase iii
advanced non small cell lung cancer
open label
clinical trial
epidermal growth factor receptor
phase ii
small cell lung cancer
double blind
placebo controlled
electronic health record
case control
study protocol
machine learning
tyrosine kinase